Rapid Dose Therapeutics Corp
Rapid Dose Therapeutics Corp., a life sciences company, provides drug delivery technologies in Canada. The company offers QuickStrip/PharmaStrip, an oral fast-dissolving drug delivery system to rapidly release into the blood stream a list of pharmaceuticals, emulsified oils, and over-the-counter medicines; QuickStrip Energy to deliver energizing caffeine; QuickStrip B12 to deliver vitamin B12 in … Read more
Rapid Dose Therapeutics Corp (RDTCF) - Total Assets
Latest total assets as of November 2025: $3.79 Million USD
Based on the latest financial reports, Rapid Dose Therapeutics Corp (RDTCF) holds total assets worth $3.79 Million USD as of November 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Rapid Dose Therapeutics Corp - Total Assets Trend (2009–2025)
This chart illustrates how Rapid Dose Therapeutics Corp’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Rapid Dose Therapeutics Corp - Asset Composition Analysis
Current Asset Composition (February 2025)
Rapid Dose Therapeutics Corp's total assets of $3.79 Million consist of 40.6% current assets and 59.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.3% |
| Accounts Receivable | $302.61K | 18.5% |
| Inventory | $247.01K | 15.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2009–2025)
This chart illustrates how Rapid Dose Therapeutics Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Rapid Dose Therapeutics Corp's current assets represent 40.6% of total assets in 2025, a decrease from 75.6% in 2009.
- Cash Position: Cash and equivalents constituted 1.3% of total assets in 2025, down from 75.6% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is accounts receivable at 18.5% of total assets.
Rapid Dose Therapeutics Corp Competitors by Total Assets
Key competitors of Rapid Dose Therapeutics Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Rapid Dose Therapeutics Corp - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Rapid Dose Therapeutics Corp generates 1.28x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Rapid Dose Therapeutics Corp is currently not profitable relative to its asset base.
Rapid Dose Therapeutics Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.20 | 0.17 |
| Quick Ratio | 0.06 | 0.15 | 0.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-7.57 Million | $ -2.52 Million | $ -3.94 Million |
Rapid Dose Therapeutics Corp - Advanced Valuation Insights
This section examines the relationship between Rapid Dose Therapeutics Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 29.59 |
| Latest Market Cap to Assets Ratio | 6.48 |
| Asset Growth Rate (YoY) | -13.3% |
| Total Assets | $1.63 Million |
| Market Capitalization | $10.60 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Rapid Dose Therapeutics Corp's assets at a significant premium ( 6.48x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Rapid Dose Therapeutics Corp's assets decreased by 13.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Rapid Dose Therapeutics Corp (2009–2025)
The table below shows the annual total assets of Rapid Dose Therapeutics Corp from 2009 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-02-28 | $1.63 Million | -13.27% |
| 2024-02-29 | $1.89 Million | -16.09% |
| 2023-02-28 | $2.25 Million | -26.77% |
| 2022-02-28 | $3.07 Million | -19.93% |
| 2021-02-28 | $3.83 Million | -10.68% |
| 2020-02-29 | $4.29 Million | -25.82% |
| 2019-02-28 | $5.78 Million | +33791.48% |
| 2018-02-28 | $17.06K | +1789.70% |
| 2017-02-28 | $903.00 | -89.61% |
| 2015-02-28 | $8.69K | +13473.44% |
| 2014-02-28 | $64.00 | -99.81% |
| 2013-02-28 | $33.48K | -84.92% |
| 2012-02-29 | $222.03K | -10.59% |
| 2011-02-28 | $248.33K | +51.52% |
| 2010-02-28 | $163.89K | +8.09% |
| 2009-02-28 | $151.62K | -- |